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Angiotensin I-converting enzyme (ACE) activity was measured with hippurylhistidylleucine as a substrate 
in isolated human glomeruli. The mean level was 2.2k0.47 mIU/mg glomerular protein. S9780, a newly 
designed competitive inhibitor of ACE, inhibited this activity by 85% at 0.3 PM. PH]S9780 specifically 
bound to isolated human glomeruli. The & value and the number of sites were 23 nM and 83 fmol/mg, 
respectively. The prodrug, S9490, and Captopril were less potent than S9780 in displacing rH]S9780 from 
its binding sites. Angiotensin I had no effect. Binding of PH]S9780 was inhibited after preincubation of the 
glomeruli with a specific polyclonal anti-human ACE antibody. These results demonstrate that ACE is pres- 
ent in human adult glomeruli. 
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1. INTRODUCTION 
The presence of angiotensin I-converting en- 
zyme or kininase II (ACE; EC 3.4.15.1) in human 
kidney [l-3], and especially in the brush border of 
the proximal tubule [4], has been extensively 
demonstrated. Localization of the enzyme in the 
glomerular capillaries is more controversial. 
Immuno-histochemical techniques, using specific 
antibodies to human renal ACE, did not detect any 
labelling in the glomerular capillaries examined in 
sections of human adult kidneys [5]. Only endo- 
thelial cells in glomeruli of fetal kidneys were lined 
with the reaction product [6]. ACE activity was 
also present in cultured human glomerular endo- 
thelial cells [7]. Results in other species are scarce. 
ACE activity was demonstrated in rabbit freshly 
isolated glomeruli [8] and in rat cultured 
glomerular endothelial cells [9]. In the present 
paper we report the presence of ACE in human 
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glomeruli. The enzyme was detected by its biologi- 
cal activity and the specific binding of a 3H- 
labelled ACE inhibitor, S9780. 
2. MATERIALS AND METHODS 
S9780 (Perindopril), its prodrug S9490 (Perin- 
doprilate) and [3H]S9780 were donated by the In- 
stitut de Recherches Servier (Neuilly, France). The 
labelled molecule was prepared by the Centre 
d’Etudes NuclCaires (Gif-sur-Yvette, France). Its 
specific activity determined by mass spectrometry 
after purification by high performance liquid 
chromatography was 55 Ci/mmol. S9490 and its 
diacid active form, S9780, are competitive in- 
hibitors of ACE synthesized by Vincent et al. [lo]. 
Captopril was a gift from Squibb (Neuilly, 
France). Angiotensin I (A I) and hippurylhistidyl- 
leucine were purchased from Sigma (St. Louis, 
MO). 
2.1. Glomerular preparations 
Human glomeruli were isolated according to 
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[ 111 from adult kidneys obtained at nephrectomy 
or judged unsuitable for transplantation. They 
were checked for purity under light microscopy. 
All the preparations studied were devoid of any 
tubular contamination. 
Human glomerular mesangial cells were cultured 
as described in [12] in Waymouth’s medium sup- 
plemented with 10% fetal bovine serum, 
100 mu/ml penicillin and 100 pg/ml strepto- 
mycin. They were studied after 4 passages. 
Dissociated cells were removed from the Petri 
dishes using a rubber policeman. Then, the cells 
were washed and suspended in 20 mM Tris-HCl 
buffer, pH 7.5, containing 135 mM NaCl, 10 mM 
KCl, 10 mM NaCH&OO and 5 mM glucose (buf- 
fer A). 
Glomerular or cellular protein concentration 
was determined according to [13]. 
2.2. ACE activity assay 
ACE activity was measured according to [14] 
with the modification described in [15] in isolated 
glomeruli which had been homogenized by sonica- 
tion. In this technique, hippuric acid formed by 
hydrolysis of hippurylhistidylleucine is measured 
spectrophotometrically at 228 nm in the aqueous 
phase obtained after a differential extraction pro- 
cedure. The incubation medium was first extracted 
with ethylacetate. Then, the ethylacetate extract 
was evaporated gently under a stream of air and re- 
extracted with a two phase system (1 M NaCl : pe- 
troleum benzine; 3 : 2, v/v). In some samples, the 
glomerular homogenate was incubated with 
0.3 ,uM S9780. One unit of ACE activity is defined 
as the amount of enzyme able to hydrolyze 1 pmol 
substrate per min. 
2.3. Binding studies 
Glomeruli or glomerular mesangial cells (50 pg 
protein) were added to tubes containing approx. 
10 nM [3H]S9780 in buffer A. Incubation was per- 
formed at 22°C under continuous gentle shaking 
usually for 20 min. Non-specific binding was 
measured in parallel in tubes containing an addi- 
tional amount of unlabelled S9780 (10 FM). Bound 
and free radioactivities were separated by filtration 
through a cellulose nitrate filter (Whatman, Maid- 
stone, England; 0.45 PM). The filter was dried 
after 3 successive washings with ice-cold 10 mM 
Tris-HCl buffer, pH 7.4, and solubilized in 8 ml of 
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ACS II (Amersham, England). 3H radioactivity 
was counted with 43% efficiency using a liquid 
scintillation spectrometer (model Rackbeta 1211; 
LKB, Malmo, Sweden). The blank value cor- 
responding to the percentage of radioactivity 
bound to the filter in the absence of glomeruli or 
glomerular cells was always lower than 0.1% of 
total radioactivity added. Specific binding was ob- 
tained by subtraction, from total binding, of bind- 
ing in the presence of 10pM unlabelled drug. It 
was expressed as fmol of S9780 bound per mg pro- 
tein. 
[3H]S9780 binding to human glomeruli was also 
measured following a l-h preincubation at 37°C 
with a specific polyclonal anti-human ACE anti- 
body at l/500 final dilution. The results were com- 
pared with those obtained in parallel in the 
presence of preimmune rabbit serum at the same 
dilution. The anti-ACE antibody was a gift of 
Doctor Alhenc-Gelas (Paris). Its characteristics 
have previously been reported [ 161. 
3. RESULTS 
3.1. ACE activity in human glomeruli 
ACE activity in homogenized human glomeruli 
was 2.2 f 0.47 mIU/mg (table 1). ACE activity 
Table 1 
Angiotensin I-converting enzyme activity in human 
glomeruli 
Preparations Angiotensin I-converting Percentage of 
studied enzyme activity inhibition by 
(code number) (mlU/mg) S9780 
2 1.73 84 
3 2.87 93 
4 1.13 88 
5 0.93 80 
30 0.78 89 
35 4.63 89 
44 2.07 92 
45 5.23 not measured 
49 1.48 74 
50 1.17 74 
Mean f SE 2.2 + 0.47 84.8 ~fr 2.3 
Preparations 2, 3, 4 and 5 were from kidneys obtained 
at nephrectomy. Preparations 30, 35, 44,45,49, 50 were 
from kidneys judged unsuitable for transplantation. 
S9780 was used at 0.3 ,LLM 
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Fig. 1. Time-course of total (0) and non-specific (0) binding of [‘HIS9780 to human glomeruli. Concentration of t3H]- 
S9780 was 10 nM. Dissociation of the [3H]S9780-glomerulus complex (A) was obtained after addition of 10 PM un- 
labelled S9780 after equilibrium had been reached. Each point is the mean of duplicates. 
was also measured in the whole renal cortex homo- 
genate in some of the samples. It was approx. 
4-times higher (8.1 f 2.8 mIU/mg) than in the cor- 
responding glomeruli (1.9 f 0.5 mIU/mg). Glo- 
merular ACE activity was strongly inhibited 
(84.8 f 2.3%) in the presence of 0.3 PM S9780. 
3.2. Binding studies 
[3H]S9780 binding to human glomeruli was 
measured as a function of time (fig. 1). Equilibrium 
was reached after 15 min and persisted until 50 
min. Specific binding represented approx. 70% of 
total binding. Addition of an excess of the un- 
labelled drug (10 ,LLM) at equilibrium produced 
displacement of (3H]S9780 from its binding sites as 
shown by the rapid decrease of bound radioactivity 
which reached the value of non-specific binding 
within 15 min. There was a linear relationship 
(r = 0.88; p<O.Ol) between [3H]S9780 bound and 
the amount of glomerular protein in the range 
tested (O-120rg/tube) in the presence of 10 nM 
[3H]S9780. The slope of the regression line in- 
dicated 39 fmol [3H]S9780 bound per mg 
glomerular protein. When human glomeruli were 
mol.mp- 
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Fig.2. Specific binding of [3H]S9780 to human glomeruli 
at equilibrium (20 min) as a function of [3H]S9780 con- 
centration (0.6 to 130 nM). Scatchard transformation is 
given in inset. The corresponding Kd value and number 
of sites are shown. Each point is the mean of duplicates. 
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incubated for 20 min with increasing concentra- 
tions of [3H]S9780 (0.6-130 nM), the amount of 
[3H]S9780 specifically bound followed a curvi- 
linear ascending curve (fig.2). No plateau was 
reached within the range of concentrations used. 
Scatchard transformation of the data (fig.2, inset) 
provided a straight line, which suggests the 
presence of one group of specific binding sites. The 
apparent Kd value and binding site capacity were 
23 nM and 83 fmol/mg glomerular protein, 
respectively. Dilution of [3H]S9780 (10 nM) with 
increasing concentrations of unlabelled S9780 
from 1 nM to 1OpM decreased the percentage of 
labelled bound product. Nearly total binding in- 
hibition was obtained at 10 yM and the concentra- 
tion corresponding to 50% specific binding at zero 
dose (EDSO) was 42 nM. This value is of the same 
magnitude as the apparent Kd value calculated 
from the Scatchard plot. Competitive inhibition 
Percent binding L3Hl S9780 
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was also studied in the presence of S9490 which is 
the prodrug of S9780, Captopril or A I which is the 
physiological substrate of ACE. EDso were 10 ,LLM 
and 400 nM for S9490 and Captopril, respectively. 
No displacement was observed with AI (fig.3). 
Specific binding of [3H]S9780 to isolated 
glomeruli was inhibited by 41% after preincuba- 
tion of the glomeruli in the presence of a poly- 
clonal anti-human ACE antiserum at l/500 final 
dilution (39.9 + 7.3 vs 67.3 f 3.7 fmol/mg; n = 7; 
p<O.Ol). In contrast, there was no inhibition of 
binding after preincubation with preimmune 
serum at the same dilution (62.3 f 4.0 fmol/mg). 
No specific binding of [3H]S9780 to cultured 
human mesangial cells was observed. 
4. DISCUSSION 
The results of this study strongly suggest the 
Fig.3. Competitive inhibition of [3H]S9780 binding to human glomeruli in the presence of increasing concentrations of 
unlabelled S9780, S9490 (prodrug) and Captopril. The effect of 10 PM angiotensin I (A I) was also studied. Each point 
is the mean of duplicates. 
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presence of ACE in human glomeruli. Hydrolysis 
of hippurylhistidylleucine is likely to reflect ACE 
activity specifically since it is markedly inhibited at 
a low concentration (0.3 PM) of an ACE inhibitor, 
S9780. Furthermore, glomeruli possess binding 
sites for S9780 which exhibit the admitted charac- 
teristics of specificity: equilibrium of binding with 
time, reversibility of binding by addition of the un- 
labelled drug, competitive inhibition of binding at 
increasing concentrations of the drug and of 
parent compounds, high affinity of binding cor- 
responding to the active concentration of S9780 in 
human plasma [17]. Finally, binding of [3H]S9780 
to human glomeruli was inhibited by an antibody 
directed against the human ACE. It was not possi- 
ble to displace [3H]S9780 from its binding sites in 
the presence of an excess of AI although S9780, 
like Captopril, is considered as a competitive in- 
hibitor [18]. This suggests that inhibition of [3H]- 
S9780 binding and enzymatic activity are due to 
binding to distinct sites. A similar conclusion 
stemmed from the results of inhibition of [3H]Cap- 
topril binding to lung membranes by peptide 
analog ACE inhibitors [19]. In this study, there 
was no correlation between inhibition of [3H]Cap- 
topril binding and ACE activity. Localization of 
ACE within the human glomerulus remains uncer- 
tain. There was no specific binding of [3H]S9780 to 
cultured human mesangial cells. One of us 
(J.-P.M, unpublished) detected a marked labelling 
of the glomerular mesangium by histoautoradio- 
graphy after in vivo administration of [3H]S9780 
to rabbits. In contrast, Mounier et al. [6], using 
immunohistochemical techniques, observed that 
ACE was present on the glomerular endothelial 
cells of the fetal kidney. These results are in agree- 
ment with those of Striker et al. [7] who studied 
cultured glomerular endothelial cells. Therefore, 
ACE distribution may be different with the 
species. 
Glomerular ACE has been demonstrated in the 
rabbit [8] and in the rat [20]. The fact that it was 
not detected previously in human adult glomeruli 
[5,6] by immunohistochemistry is probably due to 
its low concentration in this species. The tech- 
niques used in the present study allowed us to get 
over this difficulty. 
The physiological role of glomerular ACE is 
probably related to the intraglomerular formation 
of angiotensin II. Renin is synthesized by the dif- 
ferentiated epithelioid cells of the glomerular af- 
ferent arterioles but also, within the glomerulus, 
by the mesangial cells [21]. Angiotensinogen, 
which serves as a substrate for the formation of 
A I, is present in the plasma and is also synthesized 
in the renal cortex [22]. Therefore, all conditions 
are met for intraglomerular generation of AII. 
Glomerular mesangial cells and the glomerular 
arterioles are the target of this hormone which pro- 
duces essentially an increase in the glomerular in- 
tracapillary pressure and a decrease in the effective 
surface of filtration [23]. Furthermore, it becomes 
increasingly evident that intrarenally generated 
A II plays a major role in a number of conditions 
such as chronic salt depletion, adrenergic nerve 
stimulation or nephrotoxic acute renal failure [24]. 
Demonstration of ACE in glomeruli is a sup- 
plementary reason for using ACE inhibitors in the 
control of local A II generation. 
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